Key facts
- It has raised $1.0M; the latest was Early Stage VC ($1.0M) in Dec 2025.
- Notable investors include McNamara Investments, US CAN Startup.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Kalino Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Kalino Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kalino Bio
Developer of biotechnology designed to create non-surgical fertility control methods for companion animals. The company offers injectable biologics supported by veterinary research, scientific rigor, and collaborative development, incorporating accessibility for underserved communities, compatibility with veterinary practice, reduced invasiveness compared to surgery, and adaptability across diverse animal care settings, enabling veterinarians, shelters, and animal welfare organizations to manage fertility more humanely, expand care options, lower resource burdens, and align with evolving standards of compassionate animal health management.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2025
- Employees
- 2
- Website
- kalino.bio/
- Ownership
- Privately Held (backing)
Kalino Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kalino Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kalino Bio in its N-PORT filings yet. We sweep new filings monthly.